Haemonetics Corporation's (NYSE:HAE) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Haemonetics Corporation's (NYSE:HAE) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Haemonetics' (NYSE:HAE) recent performance, when its stock has declined 12% over the past month. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. Particularly, we will be paying attention to Haemonetics' ROE today.
近期Haemonetics（紐交所：HAE）的表現並不理想，股價在過去一個月中下跌了12％，因此很難激發人們的興趣。但如果仔細研究其健全的財務狀況，您可能會改變想法。鑑於基本面通常推動長期市場成果，該公司值得關注。特別是，我們今天將關注Haemonetics的ROE。
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.
淨資產收益率（ROE）是衡量公司增值和管理投資者資金有效性的測試。換句話說，它是一種盈利能力比率，用於衡量公司股東提供的資金回報率。
How Is ROE Calculated?
淨資產收益率怎麼計算？
The formula for return on equity is:
權益回報率的計算公式是：
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
淨資產收益率 = 淨利潤（從持續經營中獲得）÷ 股東權益
So, based on the above formula, the ROE for Haemonetics is:
因此，基於上述公式，Haemonetics的ROE爲：
12% = US$118m ÷ US$960m (Based on the trailing twelve months to March 2024).
12％ = US$ 118m ÷ US$ 960m（基於過去十二個月截至2024年3月）。
The 'return' is the yearly profit. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.12.
“回報”是年利潤。這意味着，公司每投資股東的1美元，就能產生0.12美元的利潤。
What Has ROE Got To Do With Earnings Growth?
ROE與盈利增長有什麼關係？
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前爲止，我們了解到ROE是衡量一家公司如何高效地產生利潤的指標。 根據公司選擇重新投資或“保留”的利潤的比例，我們能夠評估公司未來產生利潤的能力。 假設其他所有內容保持不變，則ROE和盈利保留比越高，公司的增長速度就越高，這與那些不一定具備這些特徵的公司相比。
Haemonetics' Earnings Growth And 12% ROE
Haemonetics的盈利增長和12％的ROE
At first glance, Haemonetics seems to have a decent ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 11%. This probably goes some way in explaining Haemonetics' moderate 13% growth over the past five years amongst other factors.
乍一看，Haemonetics的ROE似乎還不錯。與行業相比，我們發現平均行業ROE也在11％左右，這或許在一定程度上可以解釋Haemonetics在過去五年中適度增長13％的其他因素。
As a next step, we compared Haemonetics' net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 8.7%.
作爲下一步，我們將Haemonetics的淨收入增長與行業進行了比較，令人高興的是，我們發現該公司的增長率高於業內平均增長率8.7％。
Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. Is HAE fairly valued? This infographic on the company's intrinsic value has everything you need to know.
在估值股票時，盈利增長是一個重要的指標。投資者需要知道市場是否已經合理地反映了該公司預期的盈利增長（或下滑）。這樣做將有助於他們確定股票未來的前景，是光明還是黯淡。HAE是否被合理估值？有關該公司內在價值的信息和圖表都可在本頁找到。
Is Haemonetics Using Its Retained Earnings Effectively?
Haemonetics是否有效地利用了保留收益？
Haemonetics doesn't pay any regular dividends, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.
Haemonetics並不支付任何定期股息，這意味着其所有利潤都被再投資於業務中，這解釋了該公司已經取得的相當大的盈利增長。
Summary
總的來說，我們對偉明環保的表現非常滿意。具體而言，我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然，這導致公司的收益大幅增長。但是，最新的行業分析師預測表明，該公司的收益預計將加速增長。
In total, we are pretty happy with Haemonetics' performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.
總的來說，我們對Haemonetics的表現相當滿意。特別是，我們喜歡公司以高回報率重新投資其利潤的大部分份額，這當然導致了其收益的大幅增長。但是，了解到當前分析師的預期，我們發現該公司的收益預計將加速增長。這些分析師的預期是基於行業的整體預期，還是基於公司的基本面？請單擊此處，進入我們的分析師預測頁面。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。